Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan.Tokyo, Japan, Jan 22, 2007 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) Newswire) - Novartis Pharma K.K. and Mochida Pharmaceutical Co., Ltd. today announced that the two companies have signed a contract to co-promote the angiotensin receptor The angiotensin receptors are a class of G protein-coupled receptors with angiotensins as ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the main effector hormone. blocker (ARB) Diovan(R) (valsartan) in Japan. Based on this agreement, the two companies will begin co-promoting Diovan in February 2007. The contract of this time has been made possible because Novartis Pharma, which aims to further increase growth of Diovan with a superior effect in the ARB market where competition is intensifying, and Mochida Pharmaceutical, which desires to provide additional strengths to its business foundation in the cardiovascular area that is a focused area of the company, had a common purpose. "We are very pleased that we could build a partnership with Mochida Pharmaceutical, a company that is continuing to grow in the cardiovascular area through products such as Atelec and Epadel," says Noriyuki Baba, President, Novartis Pharma K.K. "We look forward to giving additional support to hypertensive hypertensive /hy·per·ten·sive/ (-ten´siv) 1. characterized by increased tension or pressure. 2. an agent that causes hypertension. 3. a person with hypertension. patients by providing further information to medical professions to support the efficacy and safety of Diovan." Naoyuki Mochida, President, Mochida Pharmaceutical Co., Ltd., said, "Novartis gave high marks to our company's scientific information service capabilities, and as a result selected Mochida as a co-promotion partner for Diovan, the No. 1 product in terms of sales Terms of sale Conditions under which a firm proposes to sell its goods or services for cash or credit. in the ARB market. For 40 million hypertensive patients, we are determined to continue supplying information about Diovan and Atelec, our calcium channel A Calcium channel is an ion channel which displays selective permeabiltiy to calcium ions. Examples include the voltage-dependent calcium channels and the inositol triphosphate receptor. Calcium channel blockers are used to treat hypertension. blocking agent blocking agent n. A drug that blocks transmission of nerve impulses at an autonomic receptor site, autonomic synapse, or neuromuscular junction. , quickly and extensively to medical professionals." By co-operating in this way, the two companies will be able to provide Japanese clinicians with adequate information and comprehensive data to help establish Diovan's clinical profile as a therapy for high blood pressure. About Diovan Diovan is a drug synthesized and developed by Novartis, based in Switzerland, that has been engaged in research into the renin-angiotensin system from an early stage. Diovan works by selectively blocking the AT1 receptors that are involved in blood pressure elevation. Diovan has been approved as the first-line treatment for high blood pressure in around 100 countries. In Japan, when it was launched in 2000, Diovan has been widely adopted by physicians, reflecting the extensive evidence from a large-scale clinical trial program demonstrating its superior blood pressure lowering action and cardiovascular protective effect. About Mochida Pharmaceutical Co., Ltd. Since its foundation, Mochida Pharmaceutical has made effort in the R&D of original pharmaceuticals and is now focused on 4 important areas: cardiovascular, obstetrics and gynecology obstetrics and gynecology Medical and surgical specialty concerned with the management of pregnancy and childbirth and with the health of the female reproductive system. , dermatology and emergency care. The company's major products include Atelec, a long-acting calcium channel blocker calcium channel blocker n. Any of a class of drugs that inhibit movement of calcium ions across a cell membrane, used in the treatment of cardiovascular disorders. and Epadel, a treatment for hyperlipidemia hyperlipidemia /hy·per·lip·id·emia/ (-lip?i-de´me-ah) elevated concentrations of any or all of the lipids in the plasma, including hypertriglyceridemia, hypercholesterolemia, etc. . Also, as a comprehensive group of healthcare-related companies in fields of medical devices, healthcare and drug manufacturing, it is making a wide-ranging contribution to medicine and health areas. For a fiscal year ended March 2006, the company's net income reached 4,900 million yen on net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight of 70.6 billion yen. The company employs approximately 1,800 people For more information, please visit http://www.mochida.co.jp/ About Novartis Pharma K.K. Novartis Pharma K.K. is a Japanese subsidiary of the pharmaceutical division of Novartis AG, a world leader in healthcare. In 2006, the Group's businesses achieved net sales of USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 37.0 billion(approximately JPY JPY In currencies, this is the abbreviation for the Japanese Yen. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 4294.3 billion). and net income of USD 7.2 billion (approximately JPY 835.4 billion). Approximately USD5.4 billion (approximately JPY 620.5 billion) was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 people and operate in over 140 countries around the world. For more information, please visit http://www.novartis.co.jp/ Source: Mochida Pharmaceutical Co., Ltd. Contact: Novartis Pharma K.K. Corporate Communications Group Tel +81-3-3797-8027 Fax +81-3-3797-4367 E-mail: japan.novartiscommunications@novartis.com Mochida Pharmaceutical Co., Ltd. Public Relations Tel +81-3-3225-6303 Fax +81-3-3225-6315 E-mail: webmaster @mochida.co.jp Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion